Interactive Investor
>>

Seagen Inc Ordinary Shares (NASDAQ:SGEN) Share Price

SGEN

Seagen Inc Ordinary Shares

North American company

Right Arrow 1

Healthcare

Right Arrow 2

Biotechnology

Bid

-

Ask

-

Last Traded

-

Chg

-

-

XNAS

-

Updated: -

Research

News & analysis

Loading...

Times are shown in GMT-4, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.

Company Profile

Seagen Inc. (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer and Tukysa for breast cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.Seattle Genetics Inc is a biotechnology company. The company is focused on development and commercialization of targeted therapies for the treatment of cancer. Its products are ADCETRIS (brentuximab vedotin) US and ADCETRIS (brentuximab vedotin) Canada.

NASDAQ:SGEN

US81181C1045

USD

Loading...

Loading Comparison

Latest SGEN News